Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vivos Therapeutics (VVOS) EBITDA (2020 - 2025)

Historic EBITDA for Vivos Therapeutics (VVOS) over the last 6 years, with Q3 2025 value amounting to -$4.3 million.

  • Vivos Therapeutics' EBITDA fell 7029.47% to -$4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.2 million, marking a year-over-year decrease of 2686.89%. This contributed to the annual value of -$10.6 million for FY2024, which is 3668.54% up from last year.
  • Vivos Therapeutics' EBITDA amounted to -$4.3 million in Q3 2025, which was down 7029.47% from -$4.6 million recorded in Q2 2025.
  • Over the past 5 years, Vivos Therapeutics' EBITDA peaked at -$1.8 million during Q2 2024, and registered a low of -$7.3 million during Q4 2021.
  • Its 5-year average for EBITDA is -$4.4 million, with a median of -$4.3 million in 2025.
  • Per our database at Business Quant, Vivos Therapeutics' EBITDA plummeted by 22645.84% in 2021 and then surged by 5843.33% in 2024.
  • Over the past 5 years, Vivos Therapeutics' EBITDA (Quarter) stood at -$7.3 million in 2021, then rose by 21.17% to -$5.8 million in 2022, then surged by 31.75% to -$3.9 million in 2023, then soared by 33.74% to -$2.6 million in 2024, then plummeted by 66.31% to -$4.3 million in 2025.
  • Its EBITDA stands at -$4.3 million for Q3 2025, versus -$4.6 million for Q2 2025 and -$3.7 million for Q1 2025.